Abraxis BioScience developed abraxane®, a chemotherapy in which paclitaxel (a potent taxane, which inhibits microtubule shortening) is linked to serum albumin (a blood protein). This delivery method for paclitaxel chemotherapy is less toxic than the previous delivery method, which involves toxic solvents. Abraxane® was approved by the FDA in January 2005 for as adjuvant chemotherapy for metastatic breast cancer. It is administered as intravenous injection over a period of 30 minutes at a dose of 260 mg/m2. Patients receive a median of 6 cycles of abraxane® with an average of 3 weeks between cycles. Based on the description of how paclitaxel works, in which biochemical mechanism category would you classify abraxane®?
O drugs that influence DNA structure and function
O drugs that block RNA synthesis
O drugs that block DNA synthesis
O drugs that interfere with protein synthesis